by Monash University Bone marrow aspirate showing acute myeloid leukemia. Several blasts have Auer rods. Credit: Wikipedia A landmark paper published today in the New England Journal of Medicine describes the results from a global trial across 148 sites in 23 countries, showing a 30 percent improvement in survival in patients with acute myeloid leukemia (AML). The Phase...
Researchers at Flinders University are expanding work on a promising blood test model to help predict or diagnose head and neck cancer, a difficult cancer to pick up early and treat. With cancer accounting for almost 10 million a year, the Global Burden of Disease report (2017) attributed more than 380,000 deaths to head and...
BOSTON UNIVERSITY SCHOOL OF MEDICINE (Boston)–In an effort to improve the survival of patients with myeloproliferative neoplasms, a type of leukemia, researchers inhibited a specific protein (alpha5beta1 integrin) to decrease the number of large bone marrow cells (megakaryocytes) in an experimental model. An increase in megakaryocyte numbers is thought to be the cause of many...
by Peter MacCallum Cancer Centre Peter Mac scientists have found a way to target acute myeloid leukemia (AML) at its source—a discovery that could yield a more effective treatment for this aggressive and often incurable blood cancer. Prof Mark Dawson and Dr. Laura MacPherson led the international research team, in collaboration with researchers in Europe...
by University of Minnesota Medical School A new cancer clinical trial has opened at the M Health Fairview University of Minnesota Medical Center that leverages the groundbreaking research on stem cells and natural killer (NK) cells done at the Masonic Cancer Center and applies it to attack acute myeloid leukemia (AML) and B-cell lymphoma. The...
City of Hope’s research on the new CAR T, published in Science Translational Medicine, offers hope for patients who have relapsed after commercially available CD19 immunotherapy treatments CITY OF HOPE DUARTE, Calif. — The first CAR T cell therapy targeting the B cell-activating factor receptor on cancerous cells eradicated CD19-targeted therapy-resistant human leukemia and lymphoma...
by University of Sheffield A simple arthritis drug could be an effective, low cost solution to treat patients with blood cancers such as polycythemia vera (PV) and essential thrombocythemia (ET), a breakthrough study by the University of Sheffield has shown. Led by Dr. Martin Zeidler, from the University of Sheffield’s Department of Biomedical Science and...
by American Society of Hematology New data suggest that people who have a parent, sibling, or child with blood cancer have a higher likelihood of being diagnosed with the disease. The study published online today in Blood offers the first evidence that such familial risks exist across the spectrum of hematologic malignancies. Age of diagnosis, whether the...
by University of Texas M. D. Anderson Cancer Center A study at The University of Texas MD Anderson Cancer Center identified a new therapeutic target in cancer cells and explains how new anti-cancer drugs called imipridones work by inducing cancer cell death in blood cancers, such as acute myeloid leukemia (AML) and mantle cell lymphoma. The study revealed a target in mitochondria, called caseinolytic protease P (ClpP), which, upon activation, breaks down proteins within mitochondria, a process...
by Amy Norton, Healthday Reporter (HealthDay)—A gene therapy that tweaks the immune system might offer hope to people with blood cancer that has resisted standard treatments, a new preliminary trial suggests. The cancer, called multiple myeloma, arises in certain white blood cells. It is currently incurable, but there are treatments that can help people live with the disease for years. However, most people eventually progress, and some fail to respond to the available therapies...
